Myriad Genetics, Inc. Stock price

Equities

MYGN

US62855J1043

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq 04:30:00 2024-03-18 pm EDT 5-day change 1st Jan Change
21.63 USD +2.22% Intraday chart for Myriad Genetics, Inc. -4.21% +13.01%
Sales 2024 * 828M Sales 2025 * 898M Capitalization 1.94B
Net income 2024 * -91M Net income 2025 * -63M EV / Sales 2024 * 2.32 x
Net cash position 2024 * 21.96M Net Debt 2025 * 10.91M EV / Sales 2025 * 2.18 x
P/E ratio 2024 *
-23.4 x
P/E ratio 2025 *
-35.5 x
Employees 2,700
Yield 2024 *
-
Yield 2025 *
-
Free-Float 96.33%
More Fundamentals * Assessed data
Dynamic Chart
Transcript : Myriad Genetics, Inc., Q4 2023 Earnings Call, Feb 27, 2024
Earnings Flash (MYGN) MYRIAD GENETICS Reports Q4 EPS $0.04, vs. Street Est of $0.01 MT
(MYGN) MYRIAD GENETICS Forecasts 2024 Revenue Range $820M - $840M MT
Myriad Genetics, Inc. Provides Revenue Guidance for the First Quarter 2024 CI
Myriad Genetics, Inc. Updates Revenue Guidance for the Fiscal Year 2024 CI
Myriad Genetics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Myriad Genetics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Myriad Genetics Acquires Intermountain Precision Genomics' Assets from Intermountain Health MT
Myriad Genetics, Inc. completed the acquisition of select assets of laboratory business of Intermountain Precision Genomics. CI
Myriad Genetics Names George Daneker Jr. as President, Chief Clinical Officer of Oncology MT
Myriad Genetics, Inc. Appoints George Daneker as President and Chief Clinical Officer of Oncology, Effective March 18, 2024 CI
Goldman Sachs Adjusts Myriad Genetics' Price Target to $31 From $28, Maintains Buy Rating MT
BofA Securities Adjusts Price Target on Myriad Genetics to $20 From $18, Maintains Underperform Rating MT
Myriad Genetics Agrees to Acquire Select Assets of Intermountain Precision Genomics' Laboratory Business MT
Myriad Genetics, Inc. agreed to acquire Select assets of Intermountain Health Care, Inc. CI
More news
1 day+2.22%
1 week-4.21%
Current month+3.34%
1 month-6.97%
3 months+5.77%
6 months+27.01%
Current year+13.01%
More quotes
1 week
20.89
Extreme 20.8926
22.18
1 month
20.58
Extreme 20.58
23.75
Current year
17.18
Extreme 17.18
23.75
1 year
13.82
Extreme 13.82
24.21
3 years
13.82
Extreme 13.82
36.95
5 years
9.24
Extreme 9.24
48.40
10 years
9.24
Extreme 9.24
50.44
More quotes
Managers TitleAgeSince
Chief Executive Officer 61 20-08-12
Director of Finance/CFO 49 Jan. 28
Chief Tech/Sci/R&D Officer 44 14-03-31
Members of the board TitleAgeSince
Chairman 65 09-09-15
Director/Board Member 63 22-10-30
Director/Board Member 65 20-05-26
More insiders
Date Price Change Volume
24-03-18 21.63 +2.22% 620,560
24-03-15 21.16 -0.75% 2,270,198
24-03-14 21.32 -0.98% 872,236
24-03-13 21.53 -0.19% 456,571
24-03-12 21.57 -4.47% 496,301

Delayed Quote Nasdaq, March 18, 2024 at 04:30 pm EDT

More quotes
Myriad Genetics, Inc.is a genetic testing and precision medicine company. The Company provides testing that helps assess an individual's risk for developing disease or disease progression and guides treatment decisions across medical specialties where genetic insights can significantly improve patient health care and lower health care costs, and includes corporate services, such as finance, human resources, legal and information technology. It has three key areas where it has specialized products, capabilities, and expertise: Oncology, Women's Health and Mental Health. In oncology, it offers testing for patients who have cancer and companion diagnostic tests that work with corresponding drugs and treatments. It also offers the SneakPeek Early Gender DNA Test which can reveal a baby's gender as early as six weeks into pregnancy. Its products include MyRisk, BRACAnalysis, BRACAnalysis CDx, MyChoice CDx, Prolaris, and EndoPredict, Foresight, Prequel, and SneakPeek and GeneSight.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
12
Last Close Price
21.63 USD
Average target price
24.5 USD
Spread / Average Target
+13.27%
Consensus
  1. Stock
  2. Equities
  3. Stock Myriad Genetics, Inc. - Nasdaq